SCHEMBL6001087

SCHEMBL6001087

CCC(CC)c1ccc(N(Cc2ccc(-c3csc(CN4CCN(c5ccc(C(=O)O)cc5)CC4)n3)cc2)C(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.37
CTSL P07711 3/20 0.37
CTSB P07858 3/20 0.37
CTSS P25774 3/20 0.37
S1PR1 P21453 1/20 0.37
PTPN1 P18031 2/20 0.36
PTPN2 P17706 1/20 0.36
BCL2L1 Q07817 1/20 0.35
HDAC1 Q13547 1/20 0.34
BID P55957 3/20 0.34
BCL2A1 Q16548 3/20 0.34
ALK Q9UM73 1/20 0.34
CTSK P43235 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
MMP2 P08253 1/20 0.34
MMP8 P22894 1/20 0.34
CCR5 P51681 1/20 0.34
RAB9A P51151 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000509 0.84 S1PR1 (0.46) CTSLCTSBCTSSS1PR1PTPN1
SCHEMBL6000825 0.82 PTPN1 (0.39) S1PR1PTPN1PTPN2RAB9AKDM4E
SCHEMBL6000165 0.81 HDAC3 (0.39) S1PR1PTPN1PTPN2RAB9AKDM4E
SCHEMBL6000167 0.81 PTPN1 (0.49) PTPN1PTPN2MMP2RAB9AKDM4E
SCHEMBL6000827 0.79 GCGR (0.41) PTPN1RAB9AKDM4EPOLBGAA
SCHEMBL6000508 0.78 LMNA (0.36) S1PR1PTPN1PTPN2RAB9AKDM4E
SCHEMBL6000725 0.78 PTPN2 (0.55) CHEK1CTSLCTSBCTSSPTPN1
SCHEMBL6000163 0.78 PTPN2 (0.55) CHEK1CTSLCTSBCTSSPTPN1
SCHEMBL6000965 0.78 PTPN1 (0.40) PTPN1PTPN2RAB9AKDM4EPOLB
SCHEMBL4726316 0.77 PTPN1 (0.38) S1PR1PTPN1PTPN2RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US claimed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP claimed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 CHEK1 4515/4885CTSL 4264/4885CTSB 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.